KDR and neoplasm: By the same token, administration of sunitinib, a potent multikinase (VEGFR, PDGFR, and KIT) inhibitor, to two OCCA patients with progressive disease and refractory to conventional chemotherapy resulted in markedly lower levels of CA125 and notable reduction in tumor mass [7].